Company intelligence / Profile preview

Aizen Therapeutics

San Diego, California, United Statesaizentx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has demonstrated laboratory success against multiple transmembrane receptor targets and claims higher hit rates than industry standards. No human clinical results have been reported as of May 2025.

Their technology aims to improve therapeutic stability and reduce immunogenicity compared to traditional peptide drugs.
Pipeline includes programs in discovery and IND-enabling stages targeting neurological disorders, solid tumors, and genetic diseases.
No approved or late-stage assets yet.

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Mirror Peptides (synthetic, fully D-amino acid peptides)
Industry: Biotech

Partnerships

Backed by life science venture capital funds[4]; no major pharma partnerships publicly announced as of May 2025.

Beyond the preview

Go deeper on Aizen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aizen Therapeutics.

Explore the full profile